Inhibitor Therapeutics enters $3M private placement; sells 12M shares and warrants

Inhibitor Therapeutics, Inc.

Company to sell 12,000,000 shares of common stock at $0.25/share to an institutional investor, raising $3M.
Investor receives warrants to purchase up to 7,000,000 shares at $0.35/share, exercisable for 3 years.
Proceeds from the private placement will be used for working capital and general corporate purposes.
Shares and warrant shares are subject to a 9-month lock-up agreement that restricts resale.
Closing has not yet occurred; expected within a reasonable time after the filing date.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inhibitor Therapeutics, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $3,000,000 (effective 2026-02-19).

Action: entry
Agreement: equity purchase
Counterparty: an institutional investor
Value: $3,000,000
Effective: 2026-02-19

Exact text from the filing

On February 19, 2026, Inhibitor Therapeutics, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ SPA ”) with an institutional investor (the “ Investor ”), for certain financing (the “Financing”), pursuant to which the Company has agreed to sell to the Investor 12,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”) and to issue to the Investor a Common Stock Purchase Warrant to purchase up to 7,000,000 shares of Common Stock (the “Warrant”), in consideration for the Investor’s investment of $3,000,000 therefor ($0.25 per share of Common Stock and accompanying Warrant).

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Inhibitor Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-007821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.